Related Experiment Video
Updated: Jun 9, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Polymer-drug conjugates for novel molecular targets
Joaquin Sanchis1, Fabiana Canal, Rut Lucas
1Polymer Therapeutics Laboratory, Medicinal Chemistry Department, Centro de Investigación Príncipe Felipe Av Autopista del Saler, 16. E-46012 Valencia, Spain. jsanchis@cipf.es
Nanomedicine (London, England)
|August 26, 2010
Summary
Polymer therapeutics, particularly polymer-drug conjugates, show promise beyond cancer treatment. Advances in polymer chemistry and cell biology enable new applications for these advanced drug delivery systems.
Area of Science:
- Biomedical Engineering
- Polymer Chemistry
- Nanomedicine
Background:
- Polymer therapeutics leverage the enhanced permeability and retention (EPR) effect and modular polymer-drug conjugate models.
- Early applications focused on traditional anticancer drugs for cancer therapy.
- Evolving polymer chemistry and cell biology understanding present new opportunities.
Purpose of the Study:
- To explore polymer-drug conjugates beyond conventional cancer therapy.
- To highlight new therapeutic targets in oncology.
- To discuss applications for treating other major human diseases.
Main Methods:
- Review of advancements in polymer chemistry and bioconjugation techniques.
- Analysis of polymer-drug conjugate architectures and synthetic process control.
- Exploration of combination therapy strategies and novel therapeutic targets.
Main Results:
- Polymer-drug conjugates offer a versatile platform technology.
- New strategies enable more effective and selective cancer treatments.
- Potential applications extend to various major human diseases.
Conclusions:
- Polymer-drug conjugates are a promising therapeutic platform with expanding applications.
- Further development requires control over synthesis, characterization, combination therapy, and target identification.
- These advanced therapeutics hold potential for both improved cancer treatment and management of other diseases.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:14Phase II Conjugation Reactions: Overview
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...